HC Wainwright reaffirmed their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA - Free Report) in a research report released on Monday,Benzinga reports. HC Wainwright currently has a $18.00 price objective on the stock.
TNYA has been the topic of a number of other research reports. Chardan Capital reissued a "buy" rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a report on Wednesday, December 18th. Canaccord Genuity Group restated a "buy" rating and issued a $16.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Piper Sandler reaffirmed an "overweight" rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Finally, Leerink Partners reiterated an "outperform" rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $17.33.
Get Our Latest Stock Report on TNYA
Tenaya Therapeutics Price Performance
Shares of Tenaya Therapeutics stock traded down $0.03 on Monday, reaching $1.01. 2,412,589 shares of the company traded hands, compared to its average volume of 1,964,742. The company has a 50 day moving average of $1.88 and a 200 day moving average of $2.24. Tenaya Therapeutics has a 52 week low of $0.99 and a 52 week high of $7.01. The firm has a market capitalization of $79.70 million, a PE ratio of -0.70 and a beta of 2.84.
Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. As a group, analysts anticipate that Tenaya Therapeutics will post -1.35 earnings per share for the current year.
Hedge Funds Weigh In On Tenaya Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC grew its position in Tenaya Therapeutics by 1.9% in the third quarter. FMR LLC now owns 1,345,938 shares of the company's stock worth $2,598,000 after acquiring an additional 25,503 shares in the last quarter. Geode Capital Management LLC lifted its stake in Tenaya Therapeutics by 5.4% during the third quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company's stock worth $2,502,000 after purchasing an additional 66,968 shares during the last quarter. State Street Corp boosted its holdings in shares of Tenaya Therapeutics by 0.9% in the 3rd quarter. State Street Corp now owns 1,058,898 shares of the company's stock worth $2,044,000 after purchasing an additional 9,506 shares in the last quarter. abrdn plc increased its position in shares of Tenaya Therapeutics by 9.1% during the 4th quarter. abrdn plc now owns 600,700 shares of the company's stock valued at $859,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its holdings in shares of Tenaya Therapeutics by 204.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company's stock valued at $651,000 after buying an additional 226,466 shares in the last quarter. Hedge funds and other institutional investors own 90.54% of the company's stock.
Tenaya Therapeutics Company Profile
(
Get Free Report)
Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
Read More
Before you consider Tenaya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenaya Therapeutics wasn't on the list.
While Tenaya Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
